All In MedTech

Device Trial Radar · NCT04882358

Safety & Feasibility of DSR TherApy in Heart FAiluRe pAtients With Persistent Congestion

Alfapump® DSR Feasibility Study in Subjects With Persistent Congestion Due to Heart Failure, Resistant to Loop Diuretic Treatment

Last checked: Nov 19, 2026Latest source record: Nov 9, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

24

Planned (sponsor's estimate)

Start

May 27, 2021

Primary completion

Aug 31, 2022

Study completion Dec 31, 2024

Sponsor

Lead sponsor
Sequana Medical N.V.Not on our public-company list
Sponsor type
Industry
First posted
May 11, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Feasibility and safety study of the alfapump DSR system in the treatment of volume overloaded heart failure subjects receiving high doses of loop diuretics. Up to 24 subjects will be enrolled in up to 3 centres in Republic of Georgia, and randomized into 2 parallel treatment arms. Once implanted with the alfapump DSR system they will undergo DSR therapy in 2 phases: intensive treatment phase followed by maintenance treatment phase.

Conditions

  • Heart Failure
  • Volume Overload

Interventions

  • ALFAPUMP DSR (DIRECT SODIUM REMOVAL) SYSTEMDevice

    Infusion of sodium free Dextrose 10% into peritoneal cavity to remove sodium and fluid using principles of peritoneal dialysis; sodium and ultrafiltrate will be evacuated to the bladder by the alfapump

  • SGLT2 inhibitorDrug

    treatment with a standard dose of SGLT-2 inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety - Treatment related SAETime frame: up to day 156
  2. Safety - Device related SAETime frame: up to day 156
  3. Safety - Procedure related SAETime frame: up to day 156

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Israeli-Georgian Medical Research Clinic Helsicore

    Tbilisi, Georgia

  • Tbilisi Heart & Vascular Clinic

    Tbilisi, Georgia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.